Real-world drug survival of tildrakizumab for plaque psoriasis: a 3-year international multicenter retrospective study

Tildrakizumab is a monoclonal antibody targeting interleukin-23 (IL-23) that has gained regulatory approval for moderate-to-severe plaque psoriasis in several jurisdictions.1 While phase III clinical trials have evaluated its short-term efficacy and safety, real-world evidence regarding its long-term retention is limited.2-4 Herein, we report real-world drug survival of tildrakizumab in the routine clinical setting.